Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №11 (2024) > Clinical efficacy of Holisal gel as part of complex conservative treatment of patients with inflammatory periodontal diseases

Clinical efficacy of Holisal gel as part of complex conservative treatment of patients with inflammatory periodontal diseases

Nataliia B. Petrukhina , Mikhail V. Snegirev , Mariia V. Saltovets

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Aim. To study the analgesic, anti-inflammatory and antimicrobial properties of Holisal gel when used for conservative treatment of patients with gingivitis and periodontitis.
Material and methods. A comprehensive dental examination and treatment of 40 patients aged 25 to 54 years without severe somatic pathology was conducted. The first group included 20 people diagnosed with chronic gingivitis, the second group – 20 patients with mild periodontitis. As part of the comprehensive conservative treatment in both groups, the dental gel Holisal was used. To assess the analgesic effect of the Holisal gel, patients were surveyed before and after its single use at a dental appointment. Pain was assessed using a verbal scale. To assess the effectiveness of the treatment course, a dental examination of patients with an index assessment of the condition of periodontal tissues and a PCR study of subgingival microflora were performed, comparing the indicators before treatment and 10 days after the start of treatment.
Results. A survey of patients showed that 10 minutes after a single application of Holisal gel by a dentist after professional oral hygiene, a pronounced analgesic effect was noted: the absence of pain was reported by 17 (85.0%) patients in the first group and 15 (75.0%) in the second group. During a course of treatment with Holisal gel, 10 days after the start of treatment, patients with gingivitis showed a statistically significant decrease in the Green–Vermillion hygiene index by 72.0% (<0.001), and the Muhlemann–Cowell bleeding index by 67.3% (p<0.001). In patients with periodontitis, the hygiene index decreased by 64.6% (p<0.001), the Muhlemann–Cowell bleeding index by 67.8% (p<0.001), and a statistically significant decrease in the depth of periodontal pockets was observed (from 2.1±0.2 mm to 1.3±0.2 mm, p<0.05). PCR testing of subgingival microflora showed that the use of Holisal gel as part of complex therapy contributed to the complete elimination of periodontopathogenic microflora in patients with gingivitis. In patients with periodontitis, after completion of the treatment, there was a significant decrease in the frequency of detection of such representatives of anaerobic microflora as Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis, while the rest of the studied periodontopathogens were not detected after treatment.
Conclusions. The use of Holisal gel in patients with gingivitis and mild periodontitis demonstrated a pronounced analgesic effect after a single application, as well as anti-inflammatory and antimicrobial efficacy after a 10-day course of complex conservative therapy.
Keywords: chronic gingivitis, chronic periodontitis, Holisal, periodontopathogens, analgesic effect, verbal pain scale.

About the Author

Nataliia B. Petrukhina 1 , Mikhail V. Snegirev 2 , Mariia V. Saltovets 3

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

2 National Medical Research Center for Dental and Maxillofacial Surgery, Moscow, Russia

3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

References

1. World Health Organization. WHO; Geneva: 2022. Global oral health status report – towards universal health coverage for oral health by 2030. https://www.who.int/team/noncommunicable-diseases/global-status-report-on-oral-health-2022.
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390(10100):1211-59. DOI: 10.1016/S0140-6736(17)32154-2
3. Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: a call for global action. J Clin Periodontol 2017;44:456-62. DOI: 10.1111/jcpe.12732
4. Nazir M, Al-Ansari A, Al-Khalifa K et al. Global Prevalence of Periodontal Disease and Lack of Its Surveillance. Sci World J 2020;2020: 2146160. DOI: 10.1155/2020/2146160
5. Rozier RG, Pahel BT. Patient- and population-reported outcomes in public health dentistry: Oral health-related quality of life. Dent Clin North Am 2008;52:345-65. DOI: 10.1016/j.cden.2007.12.002
6. Moya-Villaescusa MJ, Sánchez-Pérez A, Esparza-Marín J et al. Periodontal Disease and Nonsurgical Periodontal Therapy on the OHRQoL of the Patient: A Pilot Study of Case Series. Dent J (Basel) 2023;11(4):94. DOI: 10.3390/dj11040094
7. Bennadi D, Reddy CVK Oral health related quality of life. J Int Soc Prev Community Dent 2013;3(1):1-6. DOI: 10.4103/2231-0762.115700
8. Van Dyke TE, Bartold PM, Reynolds EC. The Nexus Between Periodontal Inflammation and Dysbiosis. Front Immunol 2020;(11):511. DOI: 10.3389/fimmu.2020.00511
9. Sedghi LM, Bacino M, Kapila YL. Periodontal Disease: The Good, The Bad, and The Unknown. Front Cell Infect Microbiol 2021;11:766944. DOI: 10.3389/fcimb.2021.766944
10. Hasturk H, Kantarci A. Activation and resolution of periodontal inflammation and its systemic impact. Periodontol 2000 2015;69(1):255-73. DOI: 10.1111/prd.12105
11. Yao C, Narumiya S. Prostaglandin-cytokine crosstalk in chronic inflammation. Br J Pharmacol 2019;176(3):337-54. DOI: 10.1111/bph.14530
12. Saliem SS, Bede SY, Cooper PR et al. Pathogenesis of periodontitis – A potential role for epithelial-mesenchymal transition. Jpn Dent Sci Rev 2022;58:268-78. DOI: 10.1016/j.jdsr.2022.09.001
13. Червинец В.М., Червинец Ю.В., Леонтьева А.В. и др. Микробиом полости рта у больных пародонтитом, адгезивные и биопленкообразующие свойства. Клиническая лабораторная диагностика. 2021;66(1):45-51. DOI: 10.18821/0869-2084-2021-66-1-45-51
Chervinets V.M., Chervinets Yu.V., Leont’eva A.V. et al. The microbiome of oral cavity patients with periodontitis, adhesive and biofilm forming properties. Klinicheskaya laboratornaya diagnostika. 2021;66(1):45-51. DOI: 10.18821/0869-2084-2021-66-1-45-51 (in Russian).
14. Lamont RJ, Hajishengallis GN, Jenkinson HF. Oral microbiology and immunology. Wiley-Blackwell, 2013.
15. Рабинович И.М., Петрухина Н.Б., Ших Е.В. и др. Стоматологический гель Холисал на этапе консервативного лечения воспалительных заболеваний пародонта. Стоматология. 2023;102(5):34–9. DOI: 10.17116/stomat202310205134
Rabinovich I.M., Petrukhina N.B., Shikh E.V. et al. Dental gel Cholisal at the stage of conservative treatment of inflammatory periodontal diseases. Stomatologiya. 2023;102(5):34–9. DOI: 10.17116/stomat202310205134 (in Russian).
16. Рабинович И.М., Снегирев М.В., Петрухина Н.Б. и др. Клиническая эффективность консервативного лечения пациентов с хроническим генерализованным пародонтитом с применением геля Холисал. Стоматология. 2024;103(2):24–31. DOI: 10.17116/stomat2024103021
Rabinovich IM, Snegirev MV, Petrukhina NB et al. Dental gel Cholisal at the stage of conservative treatment of inflammatory periodontal diseases. Stomatology. 2024;103(2):24–31. DOI: 10.17116/stomat 2024103021 (in Russian).
17. Максимова О.П. Роль препарата «Холисал»» в комплексном лечении заболеваний пародонта и слизистой оболочки рта. Клиническая стоматология. 2018;2(86):46-9. DOI: 10.37988/1811-153X_2018_2_46
Maksimova O.P. The role of the drug «Cholisal» in complex treatment of periodontal disease and oral mucosa. Klinicheskaya stomatologiya. 2018;2(86):46-9. DOI: 10.37988/1811-153X_2018_2_46 (in Russian).
18. Крихели Н.И., Пустовойт Е.В., Дарсигова З.Т. Эффективность применения препарата Холисал в комплексном лечении заболеваний слизистой оболочки полости рта и пародонта. Стоматология. 2022;101(6):98-102. DOI: 10.17116/stomat202210106198
Krikheli N.I., Pustovoit E.V., Darsigova Z.T. The effectiveness of the drug Cholisal in the complex treatment of oral mucosa and periodontal diseases. Stomatologiia. 2022;101(6):98-102. DOI: 10.17116/stomat202210106198 (in Russian).
19. Величко Э.В., Васильев Ю.Л. Особенности выбора современных аппликационных адгезивных форм лекарственных препаратов для лечения воспалительных заболеваний пародонта и слизистых оболочек рта. Клиническая стоматология. 2022;25(4):64-72. DOI: 10.37988/1811-153X_2022_4_64
Velichko E.V., Vasil’ev Yu.L. Eculiarities of selection of modern adhesive medications for treatment of inflammatory periodontal and oral mucosa diseases. Klinicheskaya stomatologiya. 2022;25(4):64-72. DOI: 10.37988/1811-153X_2022_4_64 (in Russian).
20. Gegout PY, Stutz C, Huck O. Gels as adjuvant to non-surgical periodontal therapy: A systematic review and meta-analysis. Heliyon 2023;9(7):e17789. DOI: 10.1016/j.heliyon.2023.e17789
21. Derman SHM, Lantwin EM, Barbe AG, Noack MJ. Does a pretreatment with a dentine hypersensitivity mouth-rinse compensate the pain caused by professional mechanical plaque removal? A single-blind randomized controlled clinical trial. Clin Oral Investig 2021;25(5):3151-60. DOI: 10.1007/s00784-020-03643-4
22. Gupta R, Kaur S, Parveen D, Kumar M. Comparative evaluation of efficacy of EMLA and needleless jet anesthesia in non-surgical periodontal therapy. J Oral Biol Craniofac Res 2018;8(2):118-21.
23. Морозов A.M., Жуков C.B., Беляк M.A. и др. О возможности оценивания болевого синдрома при помощи наиболее валидизированных шкал боли (обзор литературы). Вестник новых медицинских технологий. 2020;2:62-8. DOI: 10.24411/1609-2163-2020-16663
Morozov A.M., Zhukov S.V., Belyak M.A. et al. About the possibilities of evaluating a pain syndrome using the most validized pain scales. Journal of New Medical Technologies. 2020;2:62-8. DOI: 10.24411/1609-2163-2020-16663 (in Russian).
24. Орехова Л.Ю., Лобода Е.С., Атрушкевич В.Г. и др. Актуальность применения нестероидных противовоспалительных препаратов в пародонтологии. Пародонтология. 2021;26(3):211-22. DOI: 10.33925/1683-3759-2021-26-3-211-222
Orekhova L.Yu., Loboda E.S., Atrushkevich V.G. et al. Relevance of non-steroidal anti-inflammatory drugs in periodontology. Parodontologiya. 2021;26(3):211-22. DOI: 10.33925/1683-3759-2021-26-3-211-222 (in Russian)
25. Reynolds MA, Prudencio A, Aichelmann-Reidy ME et al. Curr Drug Non-steroidal anti-inflammatory drug (NSAID)-derived poly(anhydride-esters) in bone and periodontal regeneration. Deliv 2007;4(3):233-9. DOI: 10.2174/156720107781023866
26. Baltazar MT, Dinis-Oliveira RJ, Duarte JA et al. Antioxidant properties and associated mechanisms of salicylates. Curr Med Chem 2011;18(21):3252-64. DOI: 10.2174/092986711796391552
27. Kotowska-Rodziewicz A., Zalewska A., Maciejczyk M. A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drugs in Dentistry. Med Sci Monit 2023;29:e940635. DOI: 10.12659/MSM.940635
28. Lingappan K. NF-κB in oxidative stress. Curr Opin Toxicol 2018;(7):
81-6. DOI: 10.1016/j.cotox.2017.11.002
29. Mao X, Auer DL, Buchalla W et al. Cetylpyridinium Chloride: Mechanism of Action, Antimicrobial Efficacy in Biofilms, and Potential Risks of Resistance. Antimicrob Agents Chemother 2020. PMID: 32513792

For citation:Petrukhina N.B., Snegirev M.V., Saltovets M.V. Clinical efficacy of Holisal gel as part of complex conservative treatment of patients with inflammatory periodontal diseases. Clinical review for general practice. 2024; 5 (11): 125–134 (In Russ.). DOI: 10.47407/kr2024.5.11.00526


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru